Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Latexin pseudogene (ENSG00000253422) is a genomic sequence in humans classified as a pseudogene related in sequence to the functional latexin gene (LXN)[4]. Pseudogenes do not code for functional proteins and typically arise through gene duplication, retrotransposition, or inactivation mutations in ancestral genes[1][2][7]. Some pseudogenes may be transcribed into noncoding RNAs with possible regulatory functions, but for most—including this particular latexin pseudogene—no such role is established[1][2]. Pseudogenes are generally not considered therapeutic targets or relevant in pharmacological research. Note: - If you intended to refer to the functional LXN gene (latexin), information related to a true molecular target (carboxypeptidase inhibitor, sometimes considered in cancer or neural biology) would be appropriate.[4] - "Latexin pseudogene" refers only to a nonfunctional genetic element and not to a druggable protein or receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Latexin pseudogene.